Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that acts as an antiplatelet agent. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, which may reduce gastric irritation compared to non-enteric-coated formulations.
## Primary Indications
* **Cardiovascular risk reduction:** Prevention of myocardial infarction and stroke in patients with established cardiovascular disease or risk factors.
* **Secondary prevention:** After myocardial infarction or transient ischemic attack (TIA).
## Adult Dosing
Dosing varies based on indication and local guidelines. Common dosing strategies include:
* **Cardiovascular prevention:** Typically 75 mg to 162 mg once daily.
* **Acute management (e.g., suspected MI):** Non-enteric-coated aspirin is generally preferred for faster absorption. If Ecospirin is used in an acute setting, a higher initial dose (e.g., 325 mg) may be given, but the benefit of enteric coating in this acute scenario is debated.
## Pediatric Dosing
Aspirin use in pediatric patients is generally **avoided** due to the risk of Reye's syndrome, especially in viral illnesses. There are limited established pediatric indications and specific dosing recommendations for Ecospirin.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, but caution is advised, particularly in severe impairment, due to the potential for accumulation and increased adverse effects.
## Contraindications
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* Active peptic ulceration or history of recurrent gastrointestinal (GI) bleeding.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Severe hepatic or renal impairment.
* Severe heart failure.
* Certain bleeding disorders.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, GI bleeding, ulceration.
* **Hematologic:** Increased bleeding time, bruising, epistaxis.
* **Other:** Tinnitus (especially at higher doses), dizziness, allergic reactions.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and salicylates:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective serotonin reuptake inhibitors (SSRIs):** Increased risk of bleeding.
* **Methotrexate:** Aspirin may increase methotrexate toxicity.
* **Antihypertensives:** Aspirin may reduce the efficacy of some antihypertensives.
## Monitoring
* **Signs and symptoms of GI bleeding:** Melena, hematemesis, abdominal pain.
* **Signs and symptoms of excessive bleeding:** Easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal and hepatic function:** Periodically, especially in patients with pre-existing conditions or those on long-term therapy.
* **Tinnitus:** May indicate serum salicylate levels are approaching toxic ranges.
## Clinical Pearls
* The enteric coating may delay absorption, making it less ideal for acute situations requiring rapid antiplatelet effect.
* Despite the enteric coating, GI bleeding remains a significant risk. Patients should be advised to report any signs of bleeding immediately.
* Concomitant use with proton pump inhibitors (PPIs) may be considered for patients at high risk of GI events.
* Avoid use in children and adolescents with viral illnesses due to the risk of Reye's syndrome.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before making clinical decisions.
